{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:39:36Z","timestamp":1780472376110,"version":"3.54.1"},"reference-count":38,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"MOHW | Taiwan Centers for Disease Control","award":["MOHW109-CDC-C-315-113402"],"award-info":[{"award-number":["MOHW109-CDC-C-315-113402"]}]},{"name":"MOHW | Taiwan Centers for Disease Control","award":["MOHW110-CDC-C-315-114405"],"award-info":[{"award-number":["MOHW110-CDC-C-315-114405"]}]},{"name":"MOHW | Taiwan Centers for Disease Control","award":["MOHW111-CDC-C- 315-124305"],"award-info":[{"award-number":["MOHW111-CDC-C- 315-124305"]}]},{"name":"MOHW | Taiwan Centers for Disease Control","award":["MOHW112-CDC-C-315-134305"],"award-info":[{"award-number":["MOHW112-CDC-C-315-134305"]}]},{"name":"MOHW | Taiwan Centers for Disease Control","award":["MOHW113-CDC-C-315-144308"],"award-info":[{"award-number":["MOHW113-CDC-C-315-144308"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2024,12,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Pyrazinamide (PZA) is an important first-line drug for tuberculosis (TB) treatment by eradicating the persisting\n              <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n              complex (MTBC). Due to cost and technical challenges, end TB strategies are hampered by the lack of a simple and reliable culture-based PZA antimicrobial susceptibility testing (AST) for routine use. We initially developed a simplified chromogenic pyrazinamidase (PZase) test in the TB reference laboratory using a training set MTBC isolates with various drug-resistant profiles, and validated its performance using consecutive BACTEC MGIT 960 (MGIT)-culture-positive culture in 10 clinical laboratories. The\n              <jats:italic>pncA<\/jats:italic>\n              gene Sanger sequencing results were used as the reference, and compared to the MGIT-PZA AST. Differential diagnosis of\n              <jats:italic>Mycobacterium bovis<\/jats:italic>\n              was conducted using patented in-house real-time PCR. Of the 106 training isolates, the PZase test and MGIT-PZA AST showed 100.0% and 99.1% concordance as compared to Sanger sequencing, respectively. We found 32.1% (34\/106) isolates harbored\n              <jats:italic>pncA<\/jats:italic>\n              mutations, including one isolate with silent mutation S65S. For validation, 1,793 clinical isolates were tested including 150 duplicate isolates from specimens of the same cases and 16 isolates with uncharacterized drug resistance (UDR)-associated mutations. Excluding duplicated and UDR isolates, we identified 2.6% (43\/1,627) PZA-resistant isolates, including 1.3% (21\/1,627)\n              <jats:italic>M<\/jats:italic>\n              .\n              <jats:italic>bovis<\/jats:italic>\n              isolates. The kappa values were 0.851\u20131.000. In addition, the accuracy of the PZase test conducted by 10 laboratories was 98.5%\u2013100.0%. Our simplified PZase test demonstrated high concordance with Sanger sequencing and MGIT-PZA AST. Integrating the PZase test into routine first-line AST is effortless and represents an improvement in laboratory services for ending TB.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>IMPORTANCE<\/jats:title>\n            <jats:p>\n              We developed and validated a simple pyrazinamidase (PZase) test for pyrazinamide (PZA) antimicrobial susceptibility testing (AST). Our results demonstrated that the PZase test had high agreement with the\n              <jats:italic>pncA<\/jats:italic>\n              gene sequencing and MGIT-PZA AST. Integrating PZase test into routine AST is effortless and represents an improvement in laboratory services for ending TB.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/jcm.01227-24","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T14:00:45Z","timestamp":1731938445000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["A simplified pyrazinamidase test for\n            <i>Mycobacterium tuberculosis<\/i>\n            pyrazinamide antimicrobial susceptibility testing"],"prefix":"10.1128","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8582-7827","authenticated-orcid":false,"given":"Hsin-Hua","family":"Chan","sequence":"first","affiliation":[{"name":"Tuberculosis Research Center, Centers for Disease Control, Ministry of Health and Welfare","place":["Taipei, Taiwan"]},{"name":"Reference Laboratory of Mycobacteriology, Centers for Disease Control, Ministry of Health and Welfare","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8373-8938","authenticated-orcid":false,"given":"Yu-Chen","family":"Wang","sequence":"additional","affiliation":[{"name":"Tuberculosis Research Center, Centers for Disease Control, Ministry of Health and Welfare","place":["Taipei, Taiwan"]},{"name":"Reference Laboratory of Mycobacteriology, Centers for Disease Control, Ministry of Health and Welfare","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9378-6801","authenticated-orcid":true,"given":"Ruwen","family":"Jou","sequence":"additional","affiliation":[{"name":"Tuberculosis Research Center, Centers for Disease Control, Ministry of Health and Welfare","place":["Taipei, Taiwan"]},{"name":"Reference Laboratory of Mycobacteriology, Centers for Disease Control, Ministry of Health and Welfare","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(85)90040-6"},{"key":"e_1_3_4_3_2","first-page":"317","article-title":"Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis","volume":"10","author":"Hu Y","year":"2006","unstructured":"Hu Y, Coates AR, Mitchison DA. 2006. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 10:317\u2013322.","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_4_4_2","volume-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. 2022. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. WHO, Geneva, Switzerland."},{"key":"e_1_3_4_5_2","volume-title":"WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. 2022. WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. WHO, Geneva, Switzerland."},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(16)30190-6"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2023.08.013"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/tbed.14371"},{"key":"e_1_3_4_9_2","volume-title":"Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. 2018. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. WHO, Geneva, Switzerland."},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01775-09"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-51-1-42"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00721-2"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1164\/arrd.1974.109.1.147"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2016.03.011"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00319-23"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241600"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01162-18"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2022.102273"},{"key":"e_1_3_4_19_2","volume-title":"Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. 2023. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. 2nd ed. WHO, Geneva, Switzerland.","edition":"2"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58635-x"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001721"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mimet.2018.09.018"},{"key":"e_1_3_4_23_2","volume-title":"CLSI standard M24Susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. CLSI standard M24. Susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes. 3rd ed","edition":"3"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00570-19"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.3.1109-1114.2004"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01838-12"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmni.2021.100886"},{"key":"e_1_3_4_28_2","volume-title":"WHO consolidated guidelines on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. 2024. WHO consolidated guidelines on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection. WHO, Geneva, Switzerland."},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-21025-6"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae037"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1042\/0264-6021:3530453"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2019.00404"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2020.05.009"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.619403"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00621-2021"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2021.04.034"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01179-15"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31236-0"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100959"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01227-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01227-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T19:09:26Z","timestamp":1733944166000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.01227-24"}},"subtitle":[],"editor":[{"given":"Melissa B.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,11]]}},"alternative-id":["10.1128\/jcm.01227-24"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01227-24","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"assertion":[{"value":"2024-08-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01227-24"}}